Axial Spondyloarthritis (axSpA) Market Size, Share & Trends Analysis Report By Product
This study helps professionals make sense of complex market trends and competitive shifts affecting the axial spondyloarthritis (axspa) industry today.
What Is The Current Outlook For The Axial Spondyloarthritis (axSpA) Market By 2025?
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $6.08 billion in 2024 to $6.56 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $9.03 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
What Are The Key Driving Factors For The Growth Of The Axial Spondyloarthritis (axSpA) Market?
The increasing prevalence of spondyloarthritis is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Spondyloarthritis is a chronic illness that typically affects the axial skeleton, including the spine and sacroiliac joints. The rising cases of spondyloarthritis (axSpA) can be associated with the increasing aging population and spine injuries from even minor falls or other accidents, where various treatments are provided for pain management, inflammation control, and enhancing the patient’s quality of life suffering from axSpA. For instance, in June 2023, according to Versus Arthritis’s Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, as of the year 2022, around 60,000 individuals were afflicted with axial spondyloarthritis, and annually, approximately 2,200 adults receive a new diagnosis for this condition. Therefore, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.
Global Axial Spondyloarthritis (axSpA) Market Report Segmentation
The axial spondyloarthritis (axspa)market covered in this report is segmented —
1) By Types: Ankylosing Spondylitis (AS); Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF); Anti-Interleukin Therapy (IL); Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets; Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors; Non-Steroidal Anti-Inflammatory Drugs (NSAID); Conventional Disease Modifying Anti-Rheumatic Drugs; Glucocorticoids; Interleukin Blockers
5) By End-Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores
Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS; Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA; Asymptomatic nr-axSpA
What Are The Key Trends And Market Opportunities In The Axial Spondyloarthritis (axSpA) Sector?
Product innovations are the key trend gaining popularity in the axial spondyloarthritis (axSpA) market. Major companies operating in the axial spondyloarthritis (axSpA) market are developing new drugs to sustain their position in the market. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is used to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation as indicated by elevated C-reactive protein. These European Union (EU) authorizations represent the drug’s first global marketing licenses for axial spondyloarthritis.
Who Are The Leading Players In The Axial Spondyloarthritis (axSpA) Market?
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC
View the full axial spondyloarthritis (axspa) market report here:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
Which Region Is Projected To Hold The Largest Market Share In The Global Axial Spondyloarthritis (axSpA) Market By 2029?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310–496–7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment